View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 1, 2021

Novartis’ remibrutinib displays quick disease control in urticaria trial

The Phase IIb trial met the primary goal with remibrutinib demonstrating a statistically significant dose-response.

Novartis has reported positive Phase IIb clinical trial data where remibrutinib (LOU064) showed fast and efficient disease control in inadequately controlled chronic spontaneous urticaria (CSU) patients.

Remibrutinib is a highly selective potent oral Bruton’s tyrosine kinase (BTK) inhibitor.

The dose-finding, randomised, double-blind, placebo-controlled Phase IIb trial analysed the efficacy and safety of remibrutinib over 12 weeks in 311 subjects with at least moderately active CSU.

These subjects were poorly controlled by second-generation H1-antihistamines.

Participants were randomised to receive either varying oral doses of remibrutinib or placebo.

The trial met the primary goal with remibrutinib, showing a statistically significant dose-response against placebo with respect to change from baseline (CFB) in urticaria activity score (UAS7) at the fourth week.

All remibrutinib doses offered substantial improvements related to CFB in UAS7 at week four and week 12 and showed a quick improvement as of week one.

More subjects on remibrutinib attained a complete control with the absence of hives and itchiness, or well-controlled disease until week 12 versus placebo.

The inhibitor demonstrated a favourable safety profile and beneficial tolerability across all the tested doses without any dose-dependent pattern observed.

Novartis immunology, hepatology and dermatology development unit global head Angelika Jahreis said: “Up to 1% of the world’s population is affected by CSU and we are proud of our contribution to advancing treatment.

“The fast-onset of control achieved with this novel oral agent in patients with previously inadequately-controlled CSU is compelling, and we are excited to rapidly develop remibrutinib.”

The Phase III trials in CSU are anticipated to commence subject enrolment by the end of this year, the company noted.

Last month, Novartis decided to discontinue the CIRRUS-1 trial of experimental compound CFZ533 (iscalimab) in kidney transplant patients due to reduced efficacy.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU